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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyrightª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: Development of mediastinal masses after completion of chemotherapy in pediat-
ric patients with malignant lymphoma is worrisome and challenging to clinicians.
Methods: We performed a retrospective review of 67 patients with lymphoma treated at our
hospital from January 1, 2001 to June 1, 2013. Patients who received at least two chest
computed tomography (CT) examinations after complete remission (CR) was achieved were
further analyzed. Gallium-67 scans and positron emission tomography (PET) were recorded
and compared between these patients.
Results: Sixty-two of 67 patients reached CR, of whom 31 (22 male, 9 female) were patients
that received at least two chest CT examinations after CR. Rebound thymic hyperplasia
(RTH) was diagnosed in 21/31 patients (67.7%), including 14/23 (60.9%) and seven out of eight
(87.5%) with non-Hodgkin’s lymphoma and Hodgkin’s lymphoma, respectively. Ages ranged
from 3 years to 18 years (median 10 years). Increased radioactivity uptake of the anterior
mediastinum in gallium scans was found in nine out of 20 patients (45%) with thymic rebound.
PETwas performed in six out of 21 patients. Increased fluorodeoxyglucose (FDG)-avid uptake in
the anterior mediastinum was observed in four of six patients (66.7%) by PET. One patient
received thymectomy. No patients with RTH had lymphoma relapse within the median
follow-up period (5 years). Relapse was statistically significantly different (p Z 0.001) be-
tween patients with and without RTH.Memorial HospitaldKaohsiung Medical Center, 123 Ta-Pei Road, Niao Sung, Kaohsiung, 833, Taiwan.
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Pediatrics and Neonatology (2016), hConclusion: RTH developed in 67.7% of pediatric patients with lymphoma in CR after chemo-
therapy. The association of RTH development and lowered relapse rates has yet to be deter-
mined. Awareness of this phenomenon is important in the prevention of unnecessary surgical
intervention or chemotherapy.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Development of anterior mediastinal mass after the
completion of chemotherapy in children with malignant
lymphoma is worrisome. Although rebound thymic hyper-
plasia (RTH) is not uncommon in patients after chemo-
therapy,1 concern regarding lymphoma relapse may lead to
further unnecessary diagnostic procedures and chemo-
therapy. Differentiation of RTH from lymphoma relapse is
essential for clinicians. Furthermore, the relationship be-
tween RTH and the prognosis of lymphoma is not very clear.
Therefore,wewish to establishpossibleanswersbasedon the
review of cases treated at our facility over the past 13 years.
2. Methods
We performed a retrospective review of 67 patients diag-
nosed with non-Hodgkin’s lymphoma (NHL) or Hodgkin’s
lymphoma (HL) in a single tertiary medical center in
southern Taiwan from January 1, 2001 to December 31,
2013, with follow up to their clinical course until May 30,
2015. The responses were evaluated according to the In-
ternational Working Group response criteria.2 Complete
remission (CR) was defined as complete disappearance of
all detectable clinical evidence of disease and disease-
related symptoms if present before therapy.2,3 The defini-
tion of relapse was as follows: (1) appearance of a new
lesion(s) > 1.5 cm in any axis; (2)  50% increase in the sum
of the product of the diameters of more than one lesion
from the nadir; and (3)  50% increase in the longest
diameter of a previously identified lesion > 1 cm in short
axis from the nadir.2,3 Thymic craniocaudal extent,
maximum anteroposterior, and transverse dimensions were
measured using computed tomography (CT) scans. An in-
crease in thymus size was considered when all of the cra-
niocaudal, anteroposterior, and transverse dimensions
increased. RTH was defined as an increase in thymus size
relative to the previous CT scan when patients achieved CR
after chemotherapy. We also reviewed the results of
gallium-67 and positron emission tomography (PET) scans.
We attempted to analyze the associated risk factors for
RTH. This study was approved by the institutional review
board of the Chang Gung Memorial Hospital, Kaohsiung,
Taiwan.
2.1. Statistical analysis
All statistical analyses were performed using SPSS statistic
software, version 19.0 for Windows (IBM Company, Chicago,Chen C-H, et al., Rebound Thym
ttp://dx.doi.org/10.1016/j.pednIL, USA). We used the chi-square or Fisher exact tests to
compare the categorical variables. The chi-square test was
used initially in our study. However, if there was a quadrant
with expected frequencies < 5, the Fisher exact test was
used instead. The ManneWhitney U test was used to
compare the continuous variables. Additionally, Cox pro-
portional hazards models were fitted with covariates
selected using a backward stepwise approach. For time-
dependent analysis, cases that did not experience relapse
were right-censored at the end of the follow-up period to
control for potential differences in the duration of follow
up. A two-tailed p value < 0.05 was considered statistically
significant.
3. Results
Sixty-two of 67 patients reached CR after chemotherapy.
The follow-up period ranged from 13 months to 13 years.
Thirty-one patients (23 NHL, 8 HL; 22 male, 9 female) had
at least two chest CT studies after CR (Figures 1 and 2).
All but two patients had initial chest CT studies at the
time of lymphoma diagnosis. Of 29 patients with initial
chest CT studies, 20 patients (64.5%) had initial thoracic
disease at the time of diagnosis. Twenty-one patients
(67.7%) developed RTH (Table 1). Among the patients with
RTH, 14 patients (60.9%) were diagnosed with NHL and
seven patients (87.5%) with HL. RTH was supported by
evidence that there was a lack of uptake in other sites,
and by resolution of an enlarged thymus later. Ages
ranged from 3 years to 18 years, with a median age of
10 years. Thymus enlargement resolved gradually to
normal size within the time period of 3 months to 5 years.
Seven of 21 cases had RTH that persisted for more than
2 years. No lymphoma relapse was noted in any patients
with RTH at follow up.
Some patients with chest CT-confirmed RTH also
received gallium-67 and PET scans. Twenty of 21 patients
with RTH received gallium scan studies. Increased gallium-
67-avid radioactivities in the anterior mediastinum (1
representative is shown in Figure 3A) were noted at the
time of development of RTH in nine of 20 patients (45%).
Negative findings in the chest were noted in the other 11
patients. Fluorodeoxyglucose (FDG) PET/CT scans were
studied in six of 21 patients with RTH and four patients
(66.7%) had increased FDG-avid uptake in the anterior
mediastinum at the time of development of RTH. PET
revealed a well-defined concave mass in the upper anterior
mediastinum with visually detectable FDG activity higher
than that of the adjacent aortic arch (1 representative is
shown in Figure 3B with an early maximum standardizedic Hyperplasia after Chemotherapy in Children with Lymphoma,
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Figure 1 Assessment algorithm for patients with non-Hodgkin’s lymphoma (NHL). CT Z computed tomography.
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+ MODELuptake value (SUVmax) of 3.5 and a delayed SUVmax of
4.2). The early SUVmax of the other 3 patients was 3.33,
3.30, and 2.97, respectively. The delayed SUVmax was
3.13, 3.30, and 3.19, respectively. There were negative
chest PET scans findings in the other 2 patients.
Twenty-eight patients who did not undergo CT scan
studies at least twice were excluded from the study
initially. All 28 patients underwent gallium scan studies.
Increased radioactivity in the thymus only was noted at
the time of development of RTH in eight of 28 patients
(29%). No relapse was noted in these eight patients at
follow up. PET scans were performed on three of these
patients that did not have at least two CT studies, and one
patient (33%) had increased FDG-avid uptake in theFigure 2 Assessment algorithm for patients with Hodg
Please cite this article in press as: Chen C-H, et al., Rebound Thym
Pediatrics and Neonatology (2016), http://dx.doi.org/10.1016/j.pednthymus at the time of development of RTH. This patient
had no relapse at follow up. Two of 28 patients had relapse
at follow up. One patient had relapse in the abdomen and
bone. The PET scan showed increased FDG uptake in the
abdominal paraaortic and right common iliac lymph nodes,
right fourth rib, left pubis, bilateral femora, and right
humerus. The other patient had relapse which was limited
to the abdomen. The PET scan was not done while the
gallium scan showed increased radioactivities in the right
retroperitoneal region.
One patient had biopsy-documented RTH. She had an
enlarged thymus after completion of chemotherapy for
lymphoma. The pathology of lymphoma is shown in
Figure 4A. Chest CT showed progressive enlargement of thekin’s lymphoma (HL). CT Z computed tomography.
ic Hyperplasia after Chemotherapy in Children with Lymphoma,
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Table 1 Clinical data for 21 patients with rebound thymic hyperplasia.
Case Age (y) Sex Histology Primary tumor sites Stage Follow-up period
1 9 Female DLBCL Oropharynx II 7 y
2 12 Male ALCL Axilla, bones IV 8 y
3 5 Male T-LBL Neck, inguinal, BM IV 1 y 5 m
4 9 Female T-LBL Anterior mediastinum, pericardium, pleura IV 1 y 7 m
5 18 Male Pre-T-LBL Mediastinum, pleura IV 7 y
6 6 Male Pre-B-LBL Clavicle I 2 y
7 16 Female LBCL Anterior mediastinum III 3 y
8 5 Male ALCL Axilla I 2 y
9 3 Female Burkitt Axilla, skull IV 13 y
10 10 Male T-LBL Anterior mediastinum, pleura III 3 y
11 17 Male ALCL Anterior mediastinum III 7 y
12 3 Female T-LBL Anterior mediastinum III 11 y
13 8 Male ALCL Neck, mediastinum, BM IV 9 y
14 16 Male B-lineage Kidney, lung, BM IV 2 y
15 14 Male NS Neck, BM IV 5 y
16 11 Female NS Neck, mediastinum, lung III 2 y
17 9 Male HLa Neck, sacrococcyx III 7 y
18 17 Female NS Neck, bones IV 4 y
19 14 Male Nodular lymphocytic Submandibular I 1 y 1 m
20 8 Male Mixed Neck I 11 y
21 11 Male NS Neck, axilla, bilateral lungs IV 1 y 3 m
ALCL Z anaplastic large cell lymphoma; BM Z bone marrow; DLBCLZ diffuse large B-cell lymphoma; LBCL Z large B-cell lymphoma;
NSZ nodular sclerotic; Pre-B-LBLZ precursor B-cell lymphoblastic lymphoma; Pre-T-LBLZ precursor T-cell lymphoblastic lymphoma;
T-LBL Z T-cell lymphoblastic lymphoma.
a The pathologic specimen was too small to categorize Hodgkin’s lymphoma (HL).
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+ MODELthymus 16 months after completion of chemotherapy. A
PET scan study 2 months later still revealed increased FDG-
avid uptake in the thymus with moderate intensity. Due to
concerns that lymphoma relapse could not be excluded, a
thymectomy was eventually performed. Pathology
confirmed thymic hyperplasia (Figure 4B).
In regard to the 10/31 patients without RTH according
to the chest CT studies, increased radioactivity in the
thymus was noted in three of 10 patients by gallium scan.
One of the 10 patients underwent a PET scan study, which
showed increased FDG-avid uptake in the thymus. Inter-
estingly, five of 10 patients without RTH had relapse in
several lymph nodes at follow up (Figures 1 and 2). These
five patients were diagnosed with NHL and all had relapse
in neck lymph nodes. Other sites of relapse involved
supraclavicular, mediastinal, thymus, axillary, inguinal,
mesenteric, retroperitoneal lymph nodes, lung, bone
marrow, and central nervous system (CNS) (Table 2).
However, thymus size did not increase in the patients with
thymus involvement at the time of relapse. No patient
presented with enlargement of the thymus at the time of
relapse. All patients with thymus involvement at the time
of relapse also had other locations involved.
We compared the characteristics between patients with
and without RTH. There were no differences in age, sex,
diagnosis, stage, NHL subtypes, and chemotherapy regi-
mens. No patient (0/21) with RTH had relapse. However,
50% (5/10) of patients without RTH had relapse. Differences
in relapse were statistically significant (pZ 0.001) between
patients with and without RTH (Table 3). If analyzed in
patients with NHL only, relapse was still statisticallyPlease cite this article in press as: Chen C-H, et al., Rebound Thym
Pediatrics and Neonatology (2016), http://dx.doi.org/10.1016/j.pednsignificantly different (p Z 0.004) between patients with
and without RTH. In Cox proportional hazards models, the
hazard ratio of RTH to non-RTH associated with relapse is
0.008 (95% confidence interval, 0.000e16.540; p Z 0.217).
If analyzed in patients with NHL only, the hazard ratio of
RTH to non-RTH associated with relapse is 0.014 (95% con-
fidence interval, 0.000e17.075; p Z 0.240).4. Discussion
RTH is defined as an increase in thymus size relative to
previous CT scans when patients achieved CR after
chemotherapy. Physicians must be aware of this phenom-
enon in order to treat patients appropriately. Mis-
interpretations may cause prolongation of chemotherapy or
unnecessary radiation therapy, biopsy, needle aspiration,
or thymectomy.4e6
The development of thymic enlargement is not only
present in patients with lymphoma after chemotherapy,
but also in patients with other malignancy or conditions.7
RTH has been reported in patients with osteosarcoma,
nasopharyngeal carcinoma, germ cell tumor, synovial sar-
coma, breast cancer, colon cancer, lung cancer, and Wilms’
tumor after chemotherapy.7e9 RTH has also been described
after recovery from stress such as pneumonia, operation,
after administration of steroids, and bone marrow
transplantation.7,10,11
Very few studies reported the incidence of RTH. The
majority of previous studies present a case report or case
series with diverse diagnoses.5,7 Kissin et al12 reported thatic Hyperplasia after Chemotherapy in Children with Lymphoma,
eo.2016.02.007
Figure 3 Gallium and positron emission tomography (PET)
scans. (A) Increased gallium-67-avid radioactivities in the
anterior mediastinum in gallium scan. (B) Increased fluo-
rodeoxyglucose (FDG)-avid uptake mass in the anterior medi-
astinum in PET scan (maximum standardized uptake value
(SUVmax) early: 3.5, delayed: 4.2).
Figure 4 Microscopic findings. (A) Thymic lymphoma: the
section shows neoplastic lymphoid cells and skeletal
muscle(40x). The immunohistochemical study was suggestive
of a precursor T cell lymphoblastic lymphoma. Higher magni-
fication (400) picture located in the upper right corner. (B)
Rebound thymic hyperplasia (RTH): RTH developed after
chemotherapy in the same patient 2 years later. The section
shows thymic tissue with Hassall’s corpuscles and micro-
calcification (40x). No significant pathologic change was seen.
Higher magnification (400) picture located in the upper right
corner.
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(11.6%) with testicular teratomas after chemotherapy. Jeon
et al13 reported that overall incidence of RTH after radio-
active iodine ablation therapy for thyroid cancer was
1.49%. In our study, because the primary sites of lymphoma
did not include the chest in some patients, not all patients
had received chest CT assessment during their treatment
course. We excluded those patients who did not have at
least two chest CT studies. By comparing chest CT studies
after CR, RTH was noted in 21/31 (68%) patients who un-
derwent at least two chest CT studies. Since CT was not
performed at regular intervals for ongoing follow up, the
exact incidence of RTH in patients with lymphoma after
chemotherapy may be higher. The exact incidence of RTH
of various tumors needs further study.
The interval from the cessation of chemotherapy to the
identification of RTH ranged from 1 month to 17 months in
our study. In addition, the thymic hyperplasia persisted
from 3 months to 5 years and gradually faded. These are
similar to previous reports.7,8,12 All 21 patients with RTH in
our study were asymptomatic. However, Gerhardt et al14
reported that one patient presented with acute chestPlease cite this article in press as: Chen C-H, et al., Rebound Thym
Pediatrics and Neonatology (2016), http://dx.doi.org/10.1016/j.pednpain and dyspnea after termination of immunosuppression
following renal transplant removal. CT demonstrated a
blood-containing mediastinal tumor and a hemothorax.
Histology confirmed RTH with secondary intrathymic
bleeding.
Some reports discussed the differentiation of RTH from
lymphoma relapse through chest CT morphology. Yarom
et al7 stated that features like arrowhead-shaped triangular
structure and bilobulated configuration with convex bor-
ders, being located in the normal site of the thymus, and
homogeneous soft tissue density favored RTH. Gallium scan
is often used as a follow-up tool. However, increased
radioactivity in the anterior mediastinum in a gallium-67
scan cannot differentiate RTH from lymphoma relapse.
Mediastinal uptake of gallium-67 after chemotherapy in
children with NHL was noted.15 If chest CT is used as the
standard for diagnosing RTH, the sensitivity and specificityic Hyperplasia after Chemotherapy in Children with Lymphoma,
eo.2016.02.007
Table 2 Relapsed patients and their involved sites.
Case Age
(y)
Sex Histology Initial
stage
Locations Intervala
1 5 M T-LBL III Neck,
supraclavicular,
mediastinal LNs,
lung, paraspinal,
BM, CNS
11 m
2 12 M T-LBL III Neck, clavicular
LNs, BM
1 y 4 m
3 13 M LBCL II Neck,
supraclavicular,
anterior
mediastinal,
axilla, inguinal,
retroperitoneal,
mesenteric LNs,
BM
2 y 6 m
4 16 M T-LBL III Neck, axilla,
back,
paratracheal,
anterior
mediastinal LNs,
left pleural
effusion
6 y
5 11 M Burkitt I Neck 7 y
6 b 12 F NS III Hepatoduodenal,
celiac, retrocaval,
paraaortic,
retroperitoneal
LNs, bone
7 y
7 b 4 M Mixed III Retroperitoneal
LNs
16 y
BM Z bone marrow; CNS Z central nervous system;
LBCL Z large B-cell lymphoma; LNs Z lymph nodes;
NS Z nodular sclerotic; T-LBL Z T-cell lymphoblastic
lymphoma.
a The interval between the disease onset and relapse.
b Patients 6 and 7 were initially excluded because they
received fewer than two chest computed tomography (CT)
examinations after achieving complete remission.
Table 3 Clinical characteristics of the patients with or
without rebound thymic hyperplasia.
Characteristics No RTH
n Z 10
RTH
n Z 21
p
Age (y) 12.2 (3e17) 10.3 (3e18) 0.35
Sex (no.) (M:F) 8:2 14:7 0.31
Diagnosis 0.22
NHL 9 14
HL 1 7
Stage 1.00
IeII 2 5
IIIeIV 8 16
Relapse 5 0 0.001
HLZHodgkin’s lymphoma; NHL Z non-Hodgkin’s lymphoma;
RTH Z rebound thymic hyperplasia.
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+ MODELof a gallium-67 scan to detect RTH are 45% (9/20) and 70%
(7/10), respectively, in our study. In the past decade, the
PET scan emerged as a novel lymphoma staging and follow-
up tool. However, PET does not differentiate thymic hy-
perplasia from thymic neoplasia.16 No patients with
increased FDG-avid uptake in the anterior mediastinum in
PET scan (4 patients with RTH, 1 patient without RTH)
showed relapse in our study. Thallium-201 scan was once
reported to have accumulation in the anterior mediastinum
in thymic rebound.17,18 Inaoka et al19 and Priola et al20
reported that chemical-shift magnetic resonance image
(MRI) was a useful tool to differentiate thymic hyperplasia
from thymic tumors. Mean chemical shift ratios in the
thymic hyperplasia were lower than those in the tumor
group.19 Both signal intensity index and chemical-shift ratio
on chemical-shift MRI have high accuracy to distinguish
thymic hyperplasia from tumors.20 Diffusion-weighted MRI
may also be helpful in cases of nonsuppressing RTH onPlease cite this article in press as: Chen C-H, et al., Rebound Thym
Pediatrics and Neonatology (2016), http://dx.doi.org/10.1016/j.pednchemical-shift MRI to facilitate differentiating benign from
malignant conditions.21
No patient had relapse of lymphoma among those pa-
tients with RTH in our study. Paradoxically, five patients
had relapse of lymphoma among those patients without
RTH. The hazard ratio of RTH to non-RTH associated with
relapse was 0.008. Although there was no statistical sig-
nificance, it was possible that the enrolled number was too
small so the statistical power was too low. Heron et al22
reported that thymic hyperplasia at the time of relapse in
patients with HL was never the only finding. HL relapse with
thymus enlargement was accompanied by lymph nodes
disease in the mediastinum. Peylan-Ramu et al15 found that
all patients with mediastinal uptake of gallium-67 after
completion of chemotherapy were disease-free with a
mean follow up of 52.5 months. In our study, there were
several regions of lymph node involvement in most patients
with relapse. Thymic enlargement without other regions of
lymph node involvement can be highly suspected as RTH
and may be associated with a good feature for relapse-free
status in patients with lymphoma. Thymic hyperplasia
could represent a restoration of the host immune system,
particularly cell-mediated immunity, an immunologic
rebounding phenomenon, and it could reflect a stronger
immune surveillance for children with lymphoma and favor
successful control of lymphoma.23,24
We did not find any risk factors which were associated
with RTH. The average age in patients with RTH seemed to
be lower than that of patients without RTH, but this was not
statistically significant. Female patients seemed to be more
likely to develop RTH than male patients, but this was not
statistically significant. Because the case number is too
small, larger studies may be needed to further clarify these
associations. Jeon et al13 found a significantly decreased
incidence of RTH from the 2nd to the 5th decade of age after
radioactive iodine ablation therapy for thyroid cancer. In
each age-related subgroup, the radioactive iodine dose was
significantly higher in the RTH than the non-RTH group.
Female predominance was also noted in RTH after radio-
active iodine ablation therapy for thyroid cancer.
Our findings suggest thatwhenclinicians discover patients
had mediastinal widening at follow up of lymphoma, the
history taking and physical examinations are important to
uncover abnormal clinical manifestations. Chest CT scansic Hyperplasia after Chemotherapy in Children with Lymphoma,
eo.2016.02.007
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exist or not. If there are any new enlarged lymph nodes,
diagnostic biopsy may be arranged to rule out lymphoma
relapse. If there is only thymic enlargement without other
abnormalities, RTH is most likely. In this situation, we pro-
pose that only a close follow up is needed. However, there
were some limitations in our study. This was a retrospective
study and the case number enrolled was relatively small. A
larger prospective cohort study is needed to elucidate the
association between RTH and relapse.
In conclusion, RTH developed in 67.7% of pediatric pa-
tients with lymphoma achieving CR after chemotherapy. If
there is only thymic enlargement without other nodal dis-
eases at follow up, RTH may be considered. Otherwise, RTH
will be misclassified as thymic relapse according to the
revised response criteria.2 Therefore, isolated thymic
lesion should be considered separately on the subsequent
revised response guidelines. RTH seems to be associated
with decreased chances for relapse but this remains un-
determined. Increased uptakes in thymus in gallium-67 and
FDG-PET scans are common in patients with RTH. Aware-
ness of this phenomenon is important to prevent unnec-
essary surgical intervention or further chemotherapy.Conflicts of interest
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